Table 9.

Multiple Sclerosis Disease Course Following Onset of Mimotopic Peptide Therapy

Initial Clinical Presentation:

Ambulatory Function:

Patient required constant bilateral assistance to walk 20 meters maximum (EDSS 6.5).

Sensory Function:

Absence of sensation over right anterior leg surface of 10 year’s duration.

No other discernible sensory changes.

Clinical Presentation 8 Weeks After Commencing Treatment:

Ambulatory Function:

Patient required constant bilateral assistance to walk 50 meters (EDSS 6.5).

Sensory Function:

Some return of sensation over right anterior leg surface.

Experiencing generalized, non-irritating hyperesthesia.

Clinical Presentation 35 Weeks After Commencing Treatment:

Ambulatory Function:

Patient able to walk to walk 100 meters using walking stick for tactile balance (EDSS 6.0).

Sensory Function:

Return of sensation over right anterior leg surface.

Experiencing: generalized, non-irritating hyperesthesia and improved auditory acuity.

The Table depicts a qualitative, time-relative summation of the clinical outcome of treating a single MS patient with myelin-matched mimotopic peptides.